• Logo
  • SBMUJournals

Laser Therapy for Peyronie’s Disease: A Randomized Control Double-Blind Pilot Study

Farzad Allameh, Mohammadreza Razzaghi, Seyed Mansoor Rayegani, morteza fallahkarkan, Arash Ranjbar, Amirhosein Rahavian, Atefeh Javadi, Saleh Ghiasy, Zahra Razzaghi




Introduction: The management of Peyronie’s disease (PD) has remained a therapeutic dilemma for physicians and there is no gold standard treatment. In this paper, we decided to investigate the beneficial effect of the intralesional administration of verapamil compared with the intralesional administration of verapamil plus a low-intensity laser (LIL).

Methods: Research was activated from May 2016 to May 2018 and a total of 38 men aged 18 years and older completed the investigation. The subjects were randomly divided into 2 groups. Group 1 was composed of 22 patients that were treated only by verapamil (5 mg) plus a sham laser weekly for 6 weeks, and group 2 consisted of 22 patients that received a laser, using the BTL – 6000 HIGH-INTENSITY LASER 12 W machine and the same protocol of intralesional verapamil injection. The visual analogue scale (VAS) was used to evaluate pain during an erection, penile ultrasonography was used to measure plaque size, the penile curvature angle degree was measured using the photographs taken during an erection, and the International Index of Erectile Function questionnaire was used to assess erectile function. The follow-up treatment lasted for nine months, with visits performed in the 3rd and 9th months.

Results: All study parameters decreased significantly after treatment in both arms, but the reduction in pain and penile curvature improvements in combination therapy revealed more significant changes in 3 months (p = .035, p=.032). Nevertheless, these improvements were not seen in the follow-up session after 9 months.

Conclusion: A laser appears to be safe treatment modality in carefully-selected patients with PD. It has moderate efficacy in the short term.


Erectile dysfunction; Laser therapy; Intralesional injections; Penile curvature; Verapamil; Peyronie’s disease.


Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra‐lesional injection for Peyronie's disease. Andrology. 2013;1(1):129-32. doi: 10.1111/j.2047-2927.2012.00018.x.

Muñoz-Rangel CA, Fernandez-Vivar E, Bañuelos-Gallo RA, Gonzalez-Ojeda A, Macias-Amezcua MD, Chavez-Tostado M, et al. Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in Peyronie’s Disease. Urol J. 2015;12(2):2105-10. doi: 10.22037/uj.v12i2.2894.

Pavone C, D’Amato F, Dispensa N, Torretta F, Magno C. Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie’s disease? Analysis in 279 patients with a control group in Sicily. Arch Ital Urol Androl. 2015;87(1):20-4. doi: 10.4081/aiua.2015.1.20.

Moreland R, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res. 2002;14(5):406-10. doi: 10.1038/sj.ijir.3900875.

Tapscott AH, Hakim LS. Office-based management of impotence and Peyronie’s disease. Urol Clin North Am. 2013;40(4):521-43. doi: 10.1016/j.ucl.2013.07.003.

Mirzazadeh M, Fallahkarkan M, Hosseini J. Penile fracture epidemiology, diagnosis and management in Iran: a narrative review. Transl Androl Urol. 2017;6(2):158-66. doi: 10.21037/tau.2016.12.03.

Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 2016;13(6):2920-6. doi: 10.22037/uj.v13i6.3666.

Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol. 1997;158(4):1388-90. doi: 10.1016/s0022-5347(01)64222-8.

Toscano LJr, Rezende MV, Mello LF, Pires L, Paulillo D, Glina S. A prospective, randomized, single-blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study. Int Braz J Urol. 2016;42(5):1005-9. doi: 10.1590%2FS1677-5538.IBJU.2015.0598.

Gaspar S, Dias J, Martins F, Lopes T. Recent surgical advances in Peyronie’s Disease. Acta Med Port. 2016;29(2):131-8. doi: 10.20344/amp.6317.

Claro JA, Passerotti CC, Figueiredo Neto AC, Nardozza AJr, Ortiz V, Srougi M. An alternative non-invasive treatment for Peyronie's disease. Int Braz J Urol. 2004;30(3):199-204. doi: 10.1590/s1677-55382004000300004.

Razzaghi MR, Fallah Karkan M, Ghiasy S, Javanmard B. Laser Application in Iran Urology: A Narrative Review. J Lasers Med Sci. 2018;9(1):1-6. doi: 10.15171/jlms.2018.01.

El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013;11(3):272-7. doi: 10.1016/j.aju.2013.06.006.

Tsai SR, Hamblin MR. Biological effects and medical applications of infrared radiation. J Photochem Photobiol B. 2017;170:197-207. doi: 10.1016/j.jphotobiol.2017.04.014.

Mussttaf RA, Jenkins DFL, Jha AN. Assessing the impact of low level laser therapy (LLLT) on biological systems: a review. Int J Radiat Biol. 2019;95(2):120-43. doi: 10.1080/09553002.2019.1524944.

Johnson DE, John EJr, Harris JM, Hawkins JH. Low-level laser therapy for Peyronie's disease. Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems V. International Society for Optics and Photonics;1995. doi: 10.1117/12.209091.

Candebat Montero LH, Miranda Reyes PL, Díaz García F, González Ferro I, Barbosa Ramos F, Codorniu Furet J. Peyronie's disease: treatment with interferon and laser. Arch Esp Urol . 2008;61(3):413-23. [In Spanish].

Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798-804. doi: 10.1111/j.1365-2702.2005.01121.x.

Kelâmi A. Classification of congenital and acquired penile deviation. Urol Int. 1983;38(4):229-33. doi: 10.1159/000280897.

Pakpour AH, Zeidi IM, Yekaninejad MS, Burri A. Validation of a translated and culturally adapted Iranian version of the International Index of Erectile Function. J Sex Marital Ther. 2014;40(6):541-51. doi: 10.1080/0092623X.2013.788110.

Hussein AA, Alwaal A, Lue TF. All about Peyronie's disease. Asian J Urol. 2015;2(2):70-8. doi: 10.1016/j.ajur.2015.04.019.

Allameh F, Azghandi S, Karkan MF. Is Chemotherapy Related with Erectile Dysfunction in Non-Urologic Cancer Patients? Int J Cancer Manag. 2018;11(9): e82529. doi: 10.5812/ijcm.82529.

Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522-4. doi: 10.1016/s0022-5347(17)35291-6.

Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621-6. doi: 10.1016/s0022-5347(05)64691-5.

Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620-6. doi: 10.1016/s0090-4295(97)00700-0.

Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69(6):1181-4. doi:10.1016/j.urology.2007.02.042.

Shirazi M, Haghpanah A, Badiee M, Afrasiabi M, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467-71. doi: 10.1007/s11255-009-9522-4.

Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171(2):740-5.doi: 10.1097/01.ju.0000108060.30363.8d.

Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2016;28(5):161-6. doi: 10.1038/ijir.2016.24.

Fojecki GL, Tiessen S, Osther PJ. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. World J

Urol. 2017;35(1):1-9. doi: 10.1007/s00345-016-1834-2.

Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009;56(2):363-9. doi: 10.1016/j.eururo.2009.05.012.

Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815-21. doi: 10.1111/jsm.12275.

Chung E. Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean J Urol. 2015;56(11):775-80. doi: 10.4111/kju.2015.56.11.775.

Lue TF. Peyronie's disease: an anatomically-based hypothesis and beyond. Int J Impot Res. 2002;14(5):411-3. doi: 10.1038/sj.ijir.3900876.

El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158(6):2284-90. doi: 10.1016/s0022-5347(01)68236-3.

DOI: https://doi.org/10.22037/jlms.v10i4.26017